Free Trial

Ontrak (OTRK) Competitors

Ontrak logo
$1.82
+0.05 (+2.82%)
(As of 11/5/2024 ET)

OTRK vs. BNR, ATIP, TOI, RNLX, OPGN, PMD, MRAI, BRTX, CMAX, and BGLC

Should you be buying Ontrak stock or one of its competitors? The main competitors of Ontrak include Burning Rock Biotech (BNR), ATI Physical Therapy (ATIP), Oncology Institute (TOI), Renalytix (RNLX), OpGen (OPGN), Psychemedics (PMD), Marpai (MRAI), BioRestorative Therapies (BRTX), CareMax (CMAX), and BioNexus Gene Lab (BGLC). These companies are all part of the "healthcare" industry.

Ontrak vs.

Burning Rock Biotech (NASDAQ:BNR) and Ontrak (NASDAQ:OTRK) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 13.0% of Ontrak shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 1.9% of Ontrak shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Burning Rock Biotech's average media sentiment score of 0.00 equaled Ontrak'saverage media sentiment score.

Company Overall Sentiment
Burning Rock Biotech Neutral
Ontrak Neutral

Ontrak received 33 more outperform votes than Burning Rock Biotech when rated by MarketBeat users. Likewise, 59.38% of users gave Ontrak an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.

CompanyUnderperformOutperform
Burning Rock BiotechOutperform Votes
5
31.25%
Underperform Votes
11
68.75%
OntrakOutperform Votes
38
59.38%
Underperform Votes
26
40.63%

Burning Rock Biotech has a net margin of -111.25% compared to Ontrak's net margin of -222.54%. Burning Rock Biotech's return on equity of -74.96% beat Ontrak's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-111.25% -74.96% -53.82%
Ontrak -222.54%-238.43%-119.20%

Ontrak has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$75.70M0.41-$92.07M-$4.80-0.63
Ontrak$12.74M0.60-$27.92M-$35.23-0.05

Burning Rock Biotech has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.

Ontrak has a consensus price target of $45.00, indicating a potential upside of 2,372.53%. Given Ontrak's higher probable upside, analysts clearly believe Ontrak is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Ontrak
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ontrak beats Burning Rock Biotech on 8 of the 15 factors compared between the two stocks.

Get Ontrak News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTRK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTRK vs. The Competition

MetricOntrakhealth & allied services, not elsewhere classified IndustryMedical SectorNASDAQ Exchange
Market Cap$7.68M$1.98B$5.26B$8.58B
Dividend YieldN/A2.24%5.12%4.03%
P/E Ratio-0.0519.70119.1116.00
Price / Sales0.606.111,654.4698.09
Price / CashN/A11.7334.6231.48
Price / Book0.333.504.804.67
Net Income-$27.92M$69.56M$117.38M$223.25M
7 Day Performance-1.09%-0.97%-0.16%0.41%
1 Month Performance-6.67%-10.85%6.18%4.69%
1 Year Performance-89.54%-8.25%34.70%27.26%

Ontrak Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTRK
Ontrak
1.964 of 5 stars
$1.82
+2.8%
$45.00
+2,372.5%
-89.8%$7.68M$12.74M-0.05250Upcoming Earnings
Gap Up
BNR
Burning Rock Biotech
0.2747 of 5 stars
$2.80
-0.4%
N/A-72.3%$28.68M$509.81M-0.581,390Gap Down
ATIP
ATI Physical Therapy
1.2696 of 5 stars
$5.50
+2.2%
N/A-33.4%$23.65M$699.02M-0.405,600News Coverage
Trading Halted
TOI
Oncology Institute
2.2956 of 5 stars
$0.30
-3.2%
$2.50
+733.6%
-86.1%$22.64M$324.24M-0.38660Gap Down
RNLX
Renalytix
1.2329 of 5 stars
$0.21
+5.7%
$3.00
+1,348.6%
-80.1%$17.18M$2.29M-0.53100Upcoming Earnings
Gap Up
OPGN
OpGen
N/A$1.81
+8.4%
N/A-75.9%$13.95M$3.42M0.00100Upcoming Earnings
Gap Down
PMD
Psychemedics
N/A$2.32
-0.4%
N/A-1.3%$13.73M$22.10M-2.97140Positive News
High Trading Volume
MRAI
Marpai
N/A$0.72
-23.4%
$6.00
+733.3%
+114.3%$12.92M$37.15M-0.22150Gap Down
BRTX
BioRestorative Therapies
3.7231 of 5 stars
$1.56
flat
$18.00
+1,053.8%
-21.5%$10.80M$174,100.00-0.767Upcoming Earnings
News Coverage
Gap Up
CMAX
CareMax
3.1226 of 5 stars
$2.06
-5.1%
$45.00
+2,084.5%
-96.7%$7.87M$751.10M-0.011,450News Coverage
Gap Up
High Trading Volume
BGLC
BioNexus Gene Lab
N/A$0.38
+5.6%
N/A-7.4%$6.78M$9.18M0.0030Positive News

Related Companies and Tools


This page (NASDAQ:OTRK) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners